Scott Foraker is the founder of A2 Biotherapeutics. A2 Biotherapeutics has raised $129M in total funding. Latest round: Series B.
Scott Foraker is the CEO of A2 Biotherapeutics, a clinical-stage biotechnology company focused on selective tumor cell therapies for solid tumor cancers. He founded the company more than 15 years after personally beating cancer. Foraker led the company through its emergence from stealth mode with a $57 million Series A and a subsequent $71.5 million Series B financing.
Full founder directory · Investor directory · Company funding database · Fundraising library